Toboroz
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· 3. fázis· BioNTech SE· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· 1/2. fázis· Bristol-Myers Squibb· Forrás
Contact: Satish Kumar, Site 0057
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: paul shaw, Site 0289
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: paul shaw, Site 0182
Toboroz
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Katie Wallace, Site 0601
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· 1/2. fázis· BioNTech SE· Forrás
Toboroz
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
NCT06976892· 1. fázis· Institute of Cancer Research, United Kingdom· Forrás
Contact: Amy E Quinton
Toboroz
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· 1/2. fázis· BioNTech SE· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
NCT05093231· 2. fázis· Cambridge University Hospitals NHS Foundation Trust· Forrás
Fut, nem toboroz
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· 3. fázis· NovoCure GmbH· Forrás
Toboroz
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· 1/2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733· 3. fázis· Ivy Brain Tumor Center· Forrás
Toboroz
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
NCT05655078· University College, London· Forrás
Contact: Paul Shaw
Toboroz
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
HTL0039732 in Participants With Advanced Solid Tumours
NCT05944237· 1/2. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Toboroz
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· 2/3. fázis· Cancer Research UK· Forrás
Contact: Robert Jones, Dr
Fut, nem toboroz
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
NCT04920708· 2. fázis· Royal Marsden NHS Foundation Trust· Forrás
Fut, nem toboroz
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· 3. fázis· Celcuity Inc· Forrás
Toboroz
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891· EMD Serono Research & Development Institute, Inc.· Forrás
Contact: Najmus Iqbal (principal investigator)
Toboroz
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
NCT05613023· 3. fázis· Institute of Cancer Research, United Kingdom· Forrás
Contact: Louise Harris
Toboroz
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05085028· 3. fázis· Imperial College London· Forrás
Contact: Paul Shaw
Toboroz
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532· 1/2. fázis· Scancell Ltd· Forrás
Contact: Joe Thornton
Fut, nem toboroz
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
NCT04905069· Boston Scientific Corporation· Forrás
Toboroz
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223· 1. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
NCT04550104· 1. fázis· University of Leeds· Forrás
Contact: Paul Shaw (principal investigator)
Fut, nem toboroz
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
NCT04046133· 1. fázis· Cardiff University· Forrás
Fut, nem toboroz
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874· 1. fázis· Genentech, Inc.· Forrás
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· 3. fázis· Loxo Oncology, Inc.· Forrás
Toboroz
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· 3. fázis· University College, London· Forrás
Contact: Jim Barber (principal investigator)
Fut, nem toboroz
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03436485· 1/2. fázis· Orion Corporation, Orion Pharma· Forrás
Toboroz
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Forrás
Contact: Jacob Tanguay, MD
Fut, nem toboroz
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· 3. fázis· Eisai Inc.· Forrás
Toboroz
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576· 2/3. fázis· Cambridge University Hospitals NHS Foundation Trust· Forrás
Contact: Annabel Borley (principal investigator)
Fut, nem toboroz
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· 3. fázis· University of Birmingham· Forrás
Fut, nem toboroz
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· 3. fázis· University of Sydney· Forrás
Fut, nem toboroz
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT01566240· 3. fázis· University College, London· Forrás
Showing 50 of 51.